Persistent prostate-specific antigen expression after neoadjuvant androgen depletion: An early predictor of relapse or incomplete androgen suppression

Urology

Volumn 68, Issue 4, 2006, Pages 834-839

  Ryan, Charles J ^a   Smith, Alex ^a   Lal, Priti ^a   Satagopan, Jaya ^a   Reuter, Victor ^a   Scardino, Peter ^a   Gerald, William ^a   Scher, Howard I ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUTAMIDE; GOSERELIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER ADJUVANT THERAPY; CLINICAL ARTICLE; DNA MICROARRAY; FOLLOW UP; GENE EXPRESSION; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RELAPSE; TREATMENT FAILURE;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; FLUTAMIDE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GOSERELIN; HUMANS; MALE; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; TREATMENT FAILURE; TUMOR MARKERS, BIOLOGICAL;

EID: 33750366075     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2006.04.016     Document Type: Article

References (10)

1. Gleave M.E., Goldenberg S.L., Chin J.L., et al. Randomized comparative study of 3 versus 8-month neoadjuvant therapy before radical prostatectomy: biochemical and pathological effects. J Urol 166 (2001) 500-507
2. Aus G., Abrahamsson P.A., Ahlgren G., et al. Three-month neoadjuvant hormonal therapy before radical prostatectomy: a 7-year follow-up of a randomized controlled trial. BJU Int 90 (2002) 561-566
3. Soloway M.S., Pareek K., Sharifi R., et al. Neoadjuvant androgen ablation before radical prostatectomy in cT2bN×M0 prostate cancer: 5-year results. J Urol 167 (2002) 112-116
4. Holzbeierlein J., Lal P., LaTulippe E., et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 164 (2004) 217-227
5. Pound C.R., Partin A.W., Eisenberger M.A., et al. Natural history of progression to metastases and death from prostate cancer in men with PSA recurrence following radical prostatectomy. JAMA 281 (1999) 1591-1597
6. Kitagawa Y., Koshida K., Mizokami A., et al. Pathological effects of neoadjuvant hormonal therapy help predict progression of prostate cancer after radical prostatectomy. Int J Urol 10 (2003) 377-382
7. Titus M.A., Schell M.J., Lih F.B., et al. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res 11 (2005) 4653-4657
8. Feldman B.J., and Feldman D. The development of androgen independent prostate cancer. Nat Rev Cancer 1 (2001) 34-45
9. Scher H.I., Buchanan G., Gerald W., et al. Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer. Endocr Relat Cancer 11 (2004) 459-476
10. LaTulippe E., Satagopan J., Smith A., et al. Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Res 62 (2002) 4499-4506